Table 1 Molecular Summary of in vivo drug efficacy trials carried out by the participant countries
From: Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites
Country | Drugs studied in efficacy trials in vivo | Follow-up period (days) | Age range of study participants |
|---|---|---|---|
Burkina Faso | Dihydroartemisinin + piperaquine | 42 | 6 months - 53 years |
| Â | Artemether + lumefantrine | 28/42 | 6 months - 39 years |
| Â | Amodiaquine | 28 | 6 months - 18 years |
| Â | Amodiaquine + artesunate | 28 | 6 months - 30 years |
| Â | Amodiaquine + sulphadoxine-pyrimethamine | 42 | 6 months - 55 years |
Cameroon (Yaoundé) | Sulphadoxine-pyrimethamine | 28 | 5 - 59 months |
| Â | Amodiaquine | Â | Â |
| Â | Amodiaquine + sulphadoxine pyrimethamine | Â | Â |
Cameroon (Buea) | Artesunate + sulphadoxine-pyrimethamine | 28 | 6 - 60 months |
| Â | Amodiaquine + artesunate | Â | Â |
Kenya | Chloroquine | 14 | 5 months-18 years |
| Â | Sulphadoxine-pyrimethamine | 28 | Â |
| Â | Sulphadoxine pyrimethamine + Cotrimoxazole | Â | Â |
Mali | Chloroquine | 14 | 6 - 60 months |
| Â | Amodiaquine | 28 | Â |
| Â | Sulphadoxine-pyrimethamine | Â | Â |
Sudan | Chloroquine | 28 | 6 months - 7 years |
| Â | Sulphadoxine-pyrimethamine | Â | Â |
| Â | Artesunate + sulphadoxine-pyrimethamine | Â | Â |